Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment

Ingrid Arijs¹,², Gert De Hertogh³, Kateleen Lemaire², Roel Quintens², Leentje Van Lommel², Kristel Van Steen⁴, Peter Leemans⁴, Isabelle Cleynen¹, Gert Van Assche¹, Séverine Vermeire¹, Karel Geboes³, Frans Schuit², Paul Rutgeerts¹,⁵

¹ Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium, ² Gene Expression Unit, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Leuven, Belgium, ³ Department of Morphology and Molecular Pathology, University Hospital Gasthuisberg, Leuven, Belgium, ⁴ Department of Electrical Engineering and Computer Science (Montefiore Institute), University of Liege, Liege, Belgium, ⁵ Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospital Gasthuisberg, Leuven, Belgium

Abstract

Background: Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect. We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD.

Methodology/Principal Findings: Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4–6 weeks after their first infliximab infusion and in 12 control patients, using Affymetrix arrays. Quantitative real-time reverse-transcription PCR and immunohistochemistry were used to confirm microarray data. The dysregulation of many AMPs in colonic IBD in comparison with control colons was widely restored by infliximab therapy, and only DEFB1 expression remained significantly decreased after therapy in the colonic mucosa of IBD responders to infliximab. In ileal Crohn’s disease (CD), expression of two neuropeptides with antimicrobial activity, PYY and CHGB, was significantly decreased before therapy compared to control ileums, and ileal PYY expression remained significantly decreased after therapy in CD responders. Expression of the downregulated AMPs before and after treatment (DEFB1 and PYY) correlated with villin 1 expression, a gut epithelial cell marker, indicating that the decrease is a consequence of epithelial damage.

Conclusions/Significance: Our study shows that the dysregulation of AMPs in IBD mucosa is the consequence of inflammation, but may be responsible for perpetuation of inflammation due to ineffective clearance of microorganisms.

Introduction

Inflammatory bowel diseases (IBDs), Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial diseases of unknown etiology, characterized by chronic relapsing inflammation of the gastro-intestinal tract. Immune, genetic and environmental factors are thought to contribute to IBD [1].

Many findings suggest that the intestinal flora plays an important role in the pathogenesis of IBD. First, several knockout animal models of IBD in a germ-free environment fail to develop intestinal inflammation [2–6]. Second, recurrence of CD in the neoterminal ileum after ileal resection with ileocolonic anastomosis has been shown to be dependent on faecal stream [7]. Third, luminal contents trigger inflammation [8], and T-cell responses in CD patients are directed against the autologous bacterial flora [9]. Fourth, in CD mucosa adherent Escherichia coli has been found [10]. Finally, antibiotics and probiotics do often ameliorate the symptoms in IBD [11].

Together these points support the microbial contribution to IBD, indicating that a basic antimicrobial mucosal barrier defect could be responsible for susceptibility to this disease. The gastro-intestinal tract is constantly exposed to a wide range of microorganisms. In order to maintain the mucosal barrier integrity against these luminal microorganisms, the intestinal epithelial cells produce a variety of antimicrobial peptides (AMPs), like defensins, lysozyme and cathelicidins. AMPs contribute to innate immunity and can be considered as natural peptide antibiotics. Several recent studies indicate that an abnormal expression of AMPs may exist in IBD [12]. Patients with Crohn’s ileitis (CDI) show a reduced antibacterial activity in their intestinal mucosal extracts and display a decreased expression of the Paneth cell alpha-defensins (DEFA5 and DEFA6).
DEFB4 protein level [23]. The may be partly due to low [17–21]. The defective mRNA induction of beta-defensins in CDc LL37 cathelicidin no association with DEFA6 and in the colon. They further found a marked upregulation of subjects and UC patients, with high expression in the terminal ileum and expression decreasing as the biopsy location became more distal in the colon. They further found a marked upregulation of DEFA5 and DEFA6 expression in inflamed UC colon. As compared to UC, Crohn’s colitis (CDc) is characterized by a decreased antimicrobial activity in cationic protein extracts from colonic biopsies and an attenuated induction of beta-defensins (DEFB4/HBD-2, DEFB103), cathelicidin LL37, and antimicrobial antiproteases elafin and SLPI [17–21]. The defective mRNA induction of beta-defensins in CDc may be partly due to low DEFB4 gene copy number [22]. However, no association with DEFB4 gene copy number was found on DEFB4 protein level [23]. The DEFB1 expression was found to be decreased in both active UC and CD [18].

It can be argued, however, that the abnormal AMP status of IBD patients is the consequence of an altered interaction between barrier and microflora interaction rather than a causative factor for disturbed microbial clearance. The hypothesis for the present study was that disturbed AMP expression in IBD is a pathogenic factor. When true, the prediction is that after pharmacological suppression of inflammation the underlying defective expression of AMPs would be unmasked. However, if the alternative hypothesis is true, namely that abnormalities in AMP production are a secondary phenomenon, it can be predicted that after disappearance of inflammation the AMP expression in IBD normalizes. To distinguish between these two hypotheses, we investigated the intestinal mucosal gene expression of AMPs in active IBD patients and the impact of anti-inflammatory therapy with infliximab (Remicade; Centocor, Inc., Malvern, PA, USA), a chimeric antibody against tumor necrosis factor-alpha (TNF-alpha), on the mucosal gene expression of AMPs in IBD patients, using microarray technology.

Methods

Ethics statement

The study was carried out at the University Hospital of Gasthuisberg in Leuven (ClinicalTrials.gov number, NCT00639821). The ethics committee of the University Hospital approved the study and all individuals gave written informed consent.

Antimicrobial peptides

The name AMPs is somewhat confusing and large number of very diverse proteins has been given this name in the literature. There are the “classic” AMPs that were discovered for their action to kill microorganisms (e.g., defensins and cathelicids), and other proteins that were discovered for other biological functions but they were reported to exert antimicrobial activities (e.g., neuropeptides, chemokines and proteinase inhibitors) [24].

The PubMed database was searched using the keywords “antimicrobial peptide” and “antimicrobial protein”, and 81 peptides/proteins with reported antimicrobial activity were selected and analysed in this study (Table S1). We excluded the AMPs that were identified as chemokines [23] because of their key role in the inflammatory response in IBD.

Patients and biopsy specimens

Sixty-one patients with active IBD (24 UC, 19 CDc and 18 CDi), refractory to corticosteroids and/or immunosuppression, and a control group of 12 individuals (6 colon and 6 ileum) who underwent endoscopy for screening for polyps were studied. The patients underwent endoscopy with biopsies from diseased bowel (colon for UC and CDc, and ileum for CDi) within a week prior to the first intravenous infusion of 5 mg infliximab per kg body weight. They underwent a second endoscopy with biopsies 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if they received a loading dose of infliximab at weeks 0, 2 and 6. The biopsies were taken at sites of active inflammation but at a distance of ulcerations. In the case of healing at control endoscopy, the biopsies were obtained in the areas where lesions were present before therapy. The endoscopist was not blinded to treatment. Half of the biopsies were immediately snap-frozen in liquid nitrogen and stored at –80°C until RNA isolation and/or immunohistochemistry, except for the biopsies from 1 CDc patient after infliximab treatment which were of poor technical quality. The residual biopsies were fixed in Carnoy’s fixative for up to 5 hours and then dehydrated, cleared and paraffin-embedded for histologic examination. The features of chronic intestinal inflammation were scored in haematoxylin-eosin stained slides from the paraffin blocks of each patient using a previously reported scoring system for UC [26] and for CD [8]. The pathologists who scored the biopsies (KG and GDH) were blinded to treatment.

The response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. For UC and CDc, the response to infliximab was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for CDc [8] and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for UC [26,27]. Patients who did not achieve this healing were considered non-responders although some of them presented endoscopic and/or histologic improvement. Of the 43 colonic IBD (IBDc) patients, we identified 20 responders (8 UC and 12 CDc) and 23 non-responders (16 UC and 7 CDc). If the same response criteria of CDc were used for CDi, only one patient showed complete endoscopic and histologic healing. Therefore, we had to use less strict response criteria for CDi. Patients with a clear improvement of the ulcerations and a decrease on the histological score [8] were considered responders. Of the 18 CDi patients, we identified 8 (partial) responders and 10 non-responders.

The baseline characteristics of the patients are summarized in table 1.

RNA isolation and oligonucleotide array hybridization

Total RNA was extracted from the biopsy specimens using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The integrity and quantity of total RNA were assessed with a 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies). As previously described [28], total RNA was analyzed with the Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA), which comprised of 54675 probe sets covering the whole genome. The microarray data were deposited at Gene Expression Omnibus under the series accession number GSE16879, and the microarray data were handled in accordance with the MIAME (Minimum Information About a Microarray Experiment) guidelines.

Microarray data analysis

A glossary of terms used in the analysis is provided in Appendix S1.

The Affymetrix raw data (.cel files) were analyzed using Bioconductor tools [29] in R (version 2.7.2, http://www.r-project.org/). The robust multichip average method [30] was
performed on the Affymetrix raw data (.cel files) to obtain a log2 expression value for each probe set. Probe set annotations were obtained through the Affymetrix NetAffx website (http://www.affymetrix.com/analysis/index.affx) or the UCSC Genome Browser website (http://genome.ucsc.edu/) or the NCBI website (http://www.ncbi.nlm.nih.gov/). For comparative analysis, linear models for microarray data (LIMMA) [31] was performed for all the probe sets (34675 probe sets) present on the microarray to identify probe sets that are different between the groups, based on moderated t-statistics. To correct for multiple testing, the false discovery rate (FDR) was estimated from p-values derived from the moderated t-statistics using the method of Benjamini and Hochberg [32]. Probe sets with a >2-fold change (FC) and a FDR <0.05 were considered biologically significant. In this study, we focused on the microarray data of AMP genes. We selected the results from all performed comparative analyses for the probe sets encoding AMP genes, interleukin 8 (IL8) gene (probe set 202859_x_at) and villin 1 (VIL1) gene (probe set 205506_at) (Table S2).

Quantitative real-time reverse-transcription PCR (qPCR)

To validate the microarray data, qPCR was performed for DEFA5, DEFA6, DEFB4, DEFB1, liver expressed antimicrobial peptide 2 (LEAP2) and peptide YY (PYY). Beta-actin was used as the endogenous reference gene. Total RNA from the same samples as for microarray analysis was used. cDNA was synthesized from 0.5 μg of total RNA using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany), following the manufacturer’s protocol. Primers and dual-labeled probes were designed using Oligo/Analyzer 3.0 software (http://bioinformatics.idtdna.com/analyser/) and synthesized by Sigma-Genosys (Haverhill, UK). The oligonucleotide sequences are available upon request. Multiplex real-time PCR was performed in a final reaction volume of 25 μl on a Rotor-Gene 3000 instrument (Corbett Research, Mortlake, Australia), using QuantiTect Multiplex PCR NoROX Kit (Qiagen, Venlo, NL), according to the manufacturer’s instructions. Cycle threshold values were determined by Rotor-Gene 6.0.16 software. All samples were amplified in duplicate reactions. The relative expression of target mRNA levels were calculated as a ratio relative to the beta-actin reference mRNA [33]. Results were analyzed using the Mann-Whitney U-test for unpaired samples and Wilcoxon signed-rank test for paired samples using SPSS 16.0 software (SPSS, Chicago, IL). A p-value of <0.05 was considered significant.

**Table 1. Baseline characteristics of the UC, CDc and CDi patients.**

| Characteristics                        | UC (n = 24) | CDc (n = 19) | CDi (n = 18) |
|----------------------------------------|-------------|--------------|--------------|
| Male/Female (%)                        | 14/10 (58.3/41.7) | 11/8 (57.9/42.1) | 9/9 (50/50)  |
| Median (IQR) age at first IFX (years)  | 41.4 (31.9–50.9) | 31.8 (23.7–47.5) | 46.4 (34–55.3) |
| Median (IQR) weight at first IFX (kg)  | 72.5 (67–80.3) | 68 (60.5–77.5) | 63.5 (56.1–79.5) |
| Median (IQR) duration of disease prior to first IFX (years) | 7.3 (2.7–17.1) | 6.4 (3.1–20.9) | 22.3 (11.1–28) |
| Extent of disease                      |             |              |              |
| UC Left-sided colitis (%)              | 7 (29.2)    | NA           | NA           |
| Pancolitis (%)                         | 17 (70.8)   | NA           | NA           |
| CD Ileocolon (%)                       | NA          | 5 (26.3)     | 9 (50)       |
| Ileum (%)                              | NA          | 0 (0)        | 9 (50)       |
| Colon (%)                              | NA          | 14 (73.7)    | 0 (0)        |
| Median (IQR) C-reactive protein at first IFX (mg/dL) | 4 (1.8–19.1) | 10.2 (4.3–35) | 7.4 (2.3–10.9) |
| Concomitant medication at first IFX (%)|             |              |              |
| S-Aminosalicylates                     | 18 (75)     | 8 (42.1)     | 5 (27.8)     |
| Corticosteroids                        | 7 (29.2)    | 4 (21.1)     | 2 (11.1)     |
| Azathioprine/6-Mercaptopurine           | 15 (62.5)   | 14 (73.7)    | 7 (38.9)     |
| Methotrexate                           | 0 (0)       | 0 (0)        | 0 (0)        |
| Corticosteroids+Immunosuppressants     | 3 (12.5)    | 2 (10.5)     | 1 (6)        |
| Active smoking at first IFX (%)        | 2 (8.3)     | 6 (31.6)     | 6 (33.3)     |

IQR, interquartile range; IFX, infliximab; NA, not applicable.
doi:10.1371/journal.pone.0007984.t001

**Immunohistochemistry**

To determine the protein localization of lysozyme (LYZ), DEFA5 and DEFB1, immunohistochemical staining was performed on 5 μm-thick cryostat sections from fresh-frozen intestinal mucosal biopsies obtained during endoscopy from the IBD patients and the control individuals. All procedures were conducted at room temperature. Briefly, cryostat sections were air-dried overnight after they were cut, fixed in acetone for 10 min and rinsed in phosphate-buffered saline (PBS) for 5 min. Sections were pre-treated with Dual Endogenous Enzyme-Block Reagent (Dako Belgium nv/sa, Heverlee, Belgium) for 10 min, washed in PBS and incubated for 30 min with the primary antibody (Ab) against LYZ (rabbit polyclonal anti-human lysozyme Ab, EC 3.2.1.17, code A 0099, from Dako, dilution 1:1500), DEFA5 (mouse monoclonal anti-human alpha defensin NPS Ab, clone nr 8C8, code ab62757, from Abcam plc, Cambridge, UK, dilution 1:250) and DEFB1 (rabbit polyclonal anti-human beta defensin 1, kindly provided by Dr. Tomas Ganz, UCLA, Los Angeles, USA, dilution 1:200). After two times 5 min of washing with PBS, the sections were incubated for 30 min with the secondary antibody, PowerVision Poly-HRP-anti-mouse/rabbit/rat IgG (Klinipath BVBA, Olen, Belgium), followed by 2 times 5 min washing with...
PBS. The complex was stained with 3-amino-9-ethylcarbazole for 10 min. After color development, the sections were rinsed in distilled water and were counterstained with Mayer’s haematoxylin for 1 min. After washing with distilled water, the sections were mounted in glycerol medium (BDH, Dorset, UK). As negative controls, cryostat sections were processed as described, however without addition of the primary antibody. The stains were evaluated by two pathologists (KG and GDH) and the location of the staining product in the tissues was noted.

**Results**

**AMP expression in intestinal mucosa from IBD patients before and after first infliximab treatment**

Pairwise comparisons were performed for intestinal mucosal mRNA expression of 81 AMP genes between controls and patients before and after infliximab treatment in UC, CDc, IBDc (UC and CDc) and CDi, using LIMMA. The results (FC, p-value and FDR) of the performed comparative analyses for all the probe sets encoding AMP genes are given in Table S2. Figure 1A–F shows the individual microarray expression values for DEFB1, LEAP2, PYY, DEFA5, DEFA6 and DEFB4, respectively.

**Colonic expression.** First, we investigated whether there were differences in gene expression of AMPs in UC compared with CDc. Although no differences in expression of AMP genes at baseline reached significance comparing UC and CDc, we noted, however, that DEFB4 mRNA expression was non-significantly increased in UC at baseline as compared with CDc at baseline (FC = 3.06, FDR = 0.10) (Table S2).

Next, we studied the AMP gene expression in inflamed colonic mucosa of IBD patients and the effect of infliximab treatment on the AMP gene expression. Table 2 shows the FC of the probe sets encoding AMP genes that were significant in one of the performed comparative analyses in UC, CDc and IBDc.

DEFB1 and LEAP2 were the only AMP genes that showed a more than 2-fold and significantly reduction in mRNA expression in inflamed colon for both UC and CDc patients before infliximab treatment as compared to control colons. Moreover, DEFB1 mRNA expression remained significantly more than 2-fold lower in IBDc responders after infliximab treatment compared to control colons (Table 2). A number of AMP genes (PYY, NTS, NPY, KNG1, CST3, HIST1H2AB/HIST1H2AE and GRN) showed a more than 1.5-fold decreased expression in active IBDc before infliximab treatment as compared with control colons, but they were not
Table 2. Fold change of the probe sets encoding AMP genes that were significant (>2-fold change and FDR<0.05, underlined) in one of the performed comparative analyses in UC, CDc and IBDc.

| Probe Set ID | Gene Symbol | before T vs control colons | after T vs control colons | NR after T vs control colons | after T vs control colons |
|--------------|-------------|---------------------------|--------------------------|---------------------------|--------------------------|
| 205033_s_at  | DEF1A-A3    | 1.60*                     | 1.51                     | 1.56*                     | 0.97                     |
| 207529_at    | DEF5        | 19.17*                    | 64.58*                   | 32.79*                    | 47.12*                   |
| 207814_at    | DEF6        | 6.42*                     | 16.91*                   | 9.85*                     | 8.71                     |
| 210397_at    | DEF81       | 0.15*                     | 0.21*                    | 0.17*                     | 0.29                     |
| 207356_at    | DEF4        | 17.29*                    | 5.61*                    | 10.52*                    | 1.12                     |
| 1555745_a_at | LYZ         | 17.52*                    | 18.12*                   | 17.81*                    | 4.57                     |
| 213975_s_at  | LYZ         | 7.27*                     | 7.45*                    | 7.35*                     | 3.59                     |
| 1552362_a_at | LEAP2       | 0.34*                     | 0.38*                    | 0.36*                     | 0.55                     |
| 41469_at     | PI3         | 11.73*                    | 7.74*                    | 9.76*                     | 2.98                     |
| 203691_at    | P3          | 11.03*                    | 7.09*                    | 9.08*                     | 2.57                     |
| 204971_at    | CSA         | 5.73*                     | 5.29*                    | 5.53*                     | 1.31                     |
| 205916_at    | S100A7      | 3.93*                     | 2.29*                    | 3.09*                     | 1.03                     |
| 214370_at    | S100A8      | 3.54*                     | 2.37*                    | 2.96*                     | 0.99                     |
| 202917_s_at  | S100A8      | 119.97*                   | 65.89*                   | 92.06*                    | 1.65                     |
| 203535_at    | S100A9      | 8.24*                     | 4.84*                    | 6.51*                     | 0.83                     |
| 205863_at    | S100A12     | 5.17*                     | 3.35*                    | 4.27*                     | 0.92                     |
| 202912_at    | ADM         | 4.19*                     | 2.95*                    | 3.59*                     | 1.34                     |
| 206390_x_at  | PF4         | 4.04*                     | 2.50*                    | 3.26*                     | 1.43                     |
| 214146_s_at  | PPBP        | 3.08*                     | 1.96*                    | 2.52*                     | 1.01                     |
| 212067_at    | C1R         | 4.72*                     | 4.66*                    | 4.69*                     | 1.51                     |
| 218232_at    | C1QA        | 3.23*                     | 3.21*                    | 3.22*                     | 1.30                     |
| 203649_at    | PLA2G2A     | 4.64*                     | 5.24*                    | 4.89*                     | 3.13                     |
| 202018_at    | LTF         | 4.50*                     | 3.02*                    | 3.77*                     | 1.20                     |
| 212531_at    | LCN2        | 17.66*                    | 13.34*                   | 15.60*                    | 4.31                     |
| 205815_at    | REG3A       | 43.82*                    | 60.29*                   | 50.45*                    | 8.12                     |
| 2100037_at   | NOS2A       | 7.86*                     | 5.22*                    | 6.56*                     | 1.19                     |
| 220104_at    | ZC3HAV1     | 2.39*                     | 2.01*                    | 2.22*                     | 1.12                     |

Table 3 shows the FC of the probe sets encoding AMP genes that were significant in one of the performed comparative analyses with CDi.

In contrast, the mRNA expression of 21 AMP genes (DEFA5, DEFA6, DEFB4, LYZ, PI3, S100A7, S100A8, S100A9, S100A12, PF4, PPBP, C1QA, S100A8, S100A9, S100A12, PLA2G2A, LTF, LCN2, REG3A, NOS2A, NOS2B, and ZC3HAV1) was more than 2-fold significantly increased before treatment in active IBDc as compared with control colons. Most of the AMP genes upregulated at baseline in active IBDc decreased significantly more than 2-fold after infliximab treatment in IBDc responders compared to control colons (Table S2).

Next, we investigated the effect of infliximab on AMP gene expression in inflamed ileal mucosa of CDi patients.

Only two AMP genes (PYY and CHGB) both belonging to the neuropeptide group showed a more than 2-fold significantly decreased expression in active CDi at baseline when compared to control ileums, and PYY expression remained more than 2-fold significantly lower in CDi responders after infliximab treatment compared to control ileums (Table 3). Other AMP genes that showed a more than 1.5-fold non-significantly decreased expression in active CDi at baseline as compared with control ileums were DEF5, DEF6, DEFB1, LYP, NPY, NTS, CHGB, and KCNJ1.
REG3G and HMGB1 (Table S2). The expression of the latter genes and also CHGB remained more than 1.5-fold non-significantly lower after therapy in CDi responders than in control ileums, except for DEFA5, DEFA6 and LEAP2 (Table S2).

Eight AMP genes (DEFB4, SLPI, P3, S100A8, S100A9, ADM, LCN2 and NOS2A) were more than 2-fold significantly upregulated in CDi at baseline in comparison with control ileums. Only LCN2 mRNA expression remained more than 2-fold significantly increased after infliximab treatment in CDi responders as compared to control ileums (Table 3).

**Table 3.** Fold change of the probe sets encoding AMP genes that were significant (>=2-fold change and FDR<0.05, underlined) in one of the performed comparative analyses with CDi.

| Probe Set ID | Gene Symbol | CDi before T vs CDc before T | CDi before T vs control ileums | CDi R after T vs control ileums | CDi NR after T vs control ileums |
|--------------|-------------|------------------------------|--------------------------------|---------------------------------|---------------------------------|
| 207529 at    | DEFA5       | 6.60*                        | 0.53                           | 0.84                            | 0.45                            |
| 207814 at    | DEFA6       | 7.18*                        | 0.53                           | 0.86                            | 0.42                            |
| 207356 at    | DEFB4       | 0.71                         | 4.61*                          | 1.81                            | 3.46                            |
| 1552362_a at | LEAP2       | 13.38*                       | 0.42                           | 0.96                            | 0.61                            |
| 203021 at    | SLPI        | 0.18*                        | 4.06*                          | 2.22                            | 3.46                            |
| 41469 at     | P3          | 0.12*                        | 5.04*                          | 1.72                            | 2.98                            |
| 203691 at    | P3          | 0.11*                        | 4.44*                          | 1.17                            | 2.47                            |
| 205916 at    | S100A7      | 0.45*                        | 0.96                           | 0.86                            | 0.96                            |
| 202917_s at  | S100A8      | 1.10                         | 36.95*                         | 2.41                            | 34.58*                          |
| 203535 at    | S100A9      | 0.92                         | 5.36*                          | 1.38                            | 4.80                            |
| 206291 at    | NT5         | 33.05*                       | 0.13                           | 0.40                            | 0.13*                           |
| 204260 at    | CHGB        | 1.08                         | 0.44*                          | 0.69                            | 0.47                            |
| 211253_x at  | PYY         | 0.68*                        | 0.37*                          | 0.43*                           | 0.35*                           |
| 207080_s at  | PYY         | 0.29*                        | 0.10*                          | 0.15*                           | 0.05*                           |
| 202912 at    | ADM         | 0.36*                        | 3.30*                          | 1.53                            | 2.42                            |
| 206390_x at  | P4          | 0.60*                        | 1.82*                          | 1.46                            | 2.15*                           |
| 205500 at    | CS          | 2.14*                        | 1.73                           | 1.66                            | 1.66                            |
| 204018_x at  | HBA1/HBA2   | 2.74*                        | 1.42                           | 1.25                            | 3.16                            |
| 211699_x at  | HBA1/HBA2   | 2.83*                        | 1.42                           | 1.26                            | 3.18                            |
| 217414_x at  | HBA1/HBA2   | 2.76*                        | 1.41                           | 1.27                            | 3.33                            |
| 209458_x at  | HBA1/HBA2   | 2.82*                        | 1.37                           | 1.22                            | 3.07                            |
| 214414_x at  | HBA1/HBA2   | 2.94*                        | 1.36                           | 1.35                            | 3.23                            |
| 211745_x at  | HBA1/HBA2   | 2.87*                        | 1.40                           | 1.25                            | 3.18                            |
| 212531 at    | LCN2        | 0.63*                        | 22.20*                         | 10.54*                          | 16.22*                          |
| 205815 at    | REG3A       | 7.85*                        | 0.85                           | 1.00                            | 0.69                            |
| 231661 at    | REG3G       | 2.34*                        | 0.55                           | 1.07                            | 0.46                            |
| 210037_s at  | NOS2A       | 0.85                         | 3.38*                          | 3.02                            | 2.74                            |

*: FDR<0.05, underline: significant (>=2-fold change and FDR<0.05), R: responders; NR: non-responders, T: treatment.
doi:10.1371/journal.pone.0007984.t003

The relationship between AMPs and epithelial integrity, inflammatory activity and Paneth cell mass

We also investigated the relationship between the mRNA expression of AMPs that remained downregulated (DEFB1 in IBDc and PYY in CDi) or upregulated (DEFA5, LYZ and PLA2G2A in IBDc, and LCN2 in CDi) after therapy in responders to infliximab and markers for epithelial integrity and for inflammatory activity, respectively. The correlations were analyzed with the Spearman’s Rank Correlation test using the microarray log2 mRNA expression values, and a p-value<0.05 was considered significant (Table 4). The ileum and colon samples were analysed separately. The mRNA levels of the probe set 205506 at representing VIIA, a marker of epithelial cell content, correlated significantly with the mRNA levels of DEFB1 in the colon (Figure 2), and the correlation with PYY was borderline significant (p-value = 0.06) in the ileum. The mRNA levels of the probe set 202859_x at representing IL8, an inflammatory marker, were used to evaluate the correlation of the mRNA levels of the upregulated AMPs with the inflammatory activity. For the upregulated AMPs, the colonic mRNA levels of DEFA5, LYZ and PLA2G2A showed a positive significant correlation with the colonic mRNA levels of IL8, and there was a positive significant correlation between the ileal mRNA levels of LCN2 and IL8.

For DEFA5 and DEFA6, we observed a non-significantly decreased expression in active CDi. In the ileum, PLA2G2A can be used as a marker of Paneth cell mass. Therefore, we studied the correlation of the microarray log2 expression levels in the ileum between the alpha-defensins (DEFA5 and DEFA6) and PLA2G2A. A positive significant relationship was identified between the mRNA levels of the alpha-defensins and VIIA in the ileum.
Validation of the microarray data by qPCR

The differential mRNA expression of DEFB1, LEAP2, PYY, DEFA5, DEFA6 and DEFB4, observed by microarray analysis, was confirmed by qPCR (Figure S1, Table S3). Moreover, using qPCR we found more genes that were significantly different between the groups. However, it must be noted that the statistical criteria used for defining significance by qPCR (P-value Mann-Whitney test/Wilcoxon signed-rank test < 0.05) were less strict than the criteria used for microarray data significance by LIMMA (>2-fold change and FDR < 0.05). Also, fewer samples were studied by qPCR than by microarray analysis.

Protein localization by immunohistochemistry

Immunohistochemistry was performed to determine where DEFB1, DEFA5 and LYZ are expressed in the colonic and ileal mucosa of healthy controls and IBD patients before and after infliximab therapy.

In the normal intestine, DEFB1 was expressed in the epithelial cell compartment, with accentuation at the surface of the biopsies (Figure 3A–B). A similar expression pattern was seen in biopsies from IBD patients, both before and after infliximab treatment. We observed important epithelial cell loss in UC, CDc and CDi biopsies before treatment, leading to an overall diminished DEFB1 expression in these samples (Figure 3C–D). This loss of protein expression was only partly restored in responders after infliximab therapy (Figure 3E–F).

DEFA5 was not expressed in the normal colonic mucosa, whereas in the ileum it was mainly seen in the Paneth cells (Figure 4A–B). Colonic biopsies from untreated IBD patients frequently showed extensive epithelial defects and granulation tissue with inflammatory cells, which stained positive for DEFA5 (Figure 4C). Epithelial cell loss was also observed in the ileum of untreated CD patients. The overall diminished DEFA5 expression in these biopsies was related to a decreased number of crypts (Figure 4D). After successful infliximab therapy, there was some regeneration of the epithelial cell compartment both in the colon and ileum. DEFA5 expression in the IBD colon shifted partly from inflammatory cells to rare metaplastic Paneth cells (Figure 4E). There were no obvious differences in expression pattern of DEFA5 in ileal CD after therapy when compared with untreated CD patients (Figure 4D and F).

In healthy controls, LYZ was mainly expressed in Paneth cells in the ileum and lamina propria mononuclear cells both in the ileum and colon. Intestinal mucosal inflammation in untreated IBD patients was characterized by an influx of numerous LYZ-expressing polymorphonuclear leukocytes and histiocytes. After successful infliximab therapy, the density of mucosal inflammatory cells decreased, which resulted in a slightly diminished LYZ expression (data not shown).

Discussion

The most commonly accepted hypothesis on the IBD etiology is that abnormalities in the innate immune response by the mucosa cause a loss of tolerance to commensal microbiota and alterations in the composition of the gut microbiota. As a consequence for this defect, the host immune system is overwhelmed by bacterial antigens which lead to chronic immune-mediated intestinal injury. There is evidence that expression and regulation of defensins, a

Table 4. Results (correlation coefficient and p-value) of the Spearman’s rank correlation analyses between the remaining dysregulated AMPs after treatment in responders, VIIL and IL8, and between alpha-defensins and PLA2G2A, using the microarray log2 normalized expression values of the probe sets representing these genes.

| Probe set | Ileum samples (n = 42) | Colon samples (n = 91) |
|-----------|------------------------|------------------------|
|           | correlation coefficient | p-value                | correlation coefficient | p-value                |
| DEFBI (210397_at) and VIIL (205506_at) | 0.332 | 0.032 | 0.708 | <0.001 |
| PYY (207060_s_at) and VIIL (205506_at) | 0.289 | 0.064 | 0.409 | <0.001 |
| DEFA5 (207529_at) and IL8 (202859_x_at) | -0.416 | 0.006 | 0.22 | 0.036 |
| PLA2G2A (203649_s_at) and IL8 (202859_x_at) | 0.175 | 0.267 | 0.335 | 0.001 |
| LYZ (213975_s_at) and IL8 (202859_x_at) | 0.226 | 0.151 | 0.746 | <0.001 |
| LCN2 (212531_at) and IL8 (211506_s_at) | 0.477 | 0.001 | 0.477 | <0.001 |
| DEFA5 (207529_at) and PLA2G2A (203649_s_at) | 0.466 | 0.002 | 0.28 | 0.007 |
| DEFA6 (207814_at) and PLA2G2A (203649_s_at) | 0.565 | <0.001 | 0.31 | 0.003 |
| DEFA5 (207529_at) and VIIL (205506_at) | 0.503 | 0.001 | -0.098 | 0.353 |
| DEFA6 (207814_at) and VIIL (205506_at) | 0.43 | 0.004 | -0.125 | 0.237 |

DOI:10.1371/journal.pone.0007984.t004

Figure 2. Scatterplot representing correlation between colonic microarray log2 expression values of DEFBI and VIIL. R: responders; T: treatment.

DOI:10.1371/journal.pone.0007984.g002
class of antimicrobial peptides (AMPs), produced in the intestinal mucosa are altered in IBD [12]. Whether the abnormalities in defensins in the mucosa in IBD are primary defects or are the consequence of inflammation is still debated. Moreover, other AMPs may also play a role in the pathogenesis of chronic inflammation. A large number of AMPs have been identified, including the “classic” AMPs (e.g. defensins) and other molecules that were first discovered for other biological activities (e.g. neuropeptides) [34]. The main goal of the present study was to investigate the influence of downregulation of inflammation by infliximab, the IgG1 monoclonal antibody to TNF-alpha, on the expression of AMPs in ileal and colonic CD and in UC in comparison with normal controls, using microarray technology.

In this study we found no significant differences at baseline in AMP expression in Crohn’s colitis mucosa in comparison with UC mucosa using our strict predefined significance criteria. Our microarray studies further showed that 21 AMPs were upregulated in inflamed colon from IBD patients before infliximab treatment in comparison with normal colons. For most of these upregulated AMPs, colonic expression almost completely normalized after treatment in IBD responders compared to their baseline samples. Only the colonic expression of DEF5, LYZ, and PLA2G2A remained significantly higher after treatment in IBD responders compared to control colons. Increased expression of the former AMPs is likely due to Paneth cell metaplasia which is readily found in active colitis [12]. Noble et al. [16] also showed an increased DEF5 and DEF6 expression in UC colon, and linked this to Paneth cell metaplasia. Next, two AMPs were significantly downregulated in active IBD colitis in comparison with normal colons, namely LEAP2 and DEF61. Expression of LEAP2 [35] in IBD has not formerly been described. The LEAP2 colonic expression increased non-significantly in IBD responders after infliximab therapy but did not normalize completely. DEF61 colonic expression remained significantly decreased in IBD responders after infliximab therapy. The expression of a number of AMP genes were dysregulated at baseline between ileal and colonic CD. In active ileal Crohn’s disease before treatment 8 AMPs were upregulated versus control ileums, whereas DEF5, DEF6, DEF61 and LEAP2 were downregulated although not significantly. Only PYY and CHGB were significantly downregulated in ileal CD.

![Image](image-url)
prior to therapy as compared to control ileums, and PYY remained significantly lower after therapy in ileal CD responders. Quantitative real-time reverse-transcription PCR and immunohistochemistry confirmed the microarray data.

In this study the close relationship between the remaining downregulated AMPs after treatment (DEFB1 and PYY) with villin 1, a marker of epithelial cell mass, strongly suggests that the decreased expression of these AMPs is the consequence of epithelial cell and enterochromaffine cell damage and loss. It was also shown with immunohistochemistry that although there is epithelial layer restoration after treatment with infliximab in responders, this restoration is incomplete and epithelial cell mass is still decreased in comparison with normals. Similarly, in the ileum the expression of alpha-defensins (DEFA5 and DEFA6) correlated well with the expression of PLA2G2A, a marker for Paneth cells, which suggests that Paneth cell loss is responsible for the non-significantly decreased alpha-defensin expression in ileal CD. This is in accordance with the data published by Simms et al. [15].

We also found no differences in expression of AMPs between patients with CARD15 mutation(s) and patients without CARD15 mutation (data not shown) similar to the findings by Simms et al. [15]. These authors found no significant relationship between the alpha-defensin (DEFA5 and DEFA6) expression and CARD15 mutation in ileal Crohn’s disease. Because of the low number of observations in our present study, we think further studies are necessary.

Our study suggests that decreased expression of antimicrobial peptides in IBD is not a primary defect causing the disease but a consequence of epithelial cell loss in the ileum and colon, and loss of Paneth cells in the ileum in an active phase of the disease. We further hypothesize that decreased secretion of AMPs as a consequence of epithelial damage in established IBD may contribute to the perpetuation of inflammation because ongoing bacterial invasion of the mucosa cannot be controlled, even despite Paneth cell metaplasia resulting in an increased production of some of the AMPs in the colon.

![Figure 4. Immunohistochemical detection of DEFA5 protein in intestinal mucosa.](image-url) No immunostaining can be seen in normal colon (A), while Paneth cells and follicle centers in Peyer’s patches are immunoreactive in normal ileum (B). Mucosal defects with inflammatory cells staining for DEFA5 in untreated UC (C) and Paneth cell loss with diminished DEFA5 staining in active CD (D). Rare DEFA5-positive metaplastic Paneth cells in colonic mucosa of UC responders after infliximab (E). No difference in DEFA5 immunoreactivity when comparing CDi responders with untreated CDi (F). (OM [A]: x100; OM [B–F]: x50). doi:10.1371/journal.pone.0007984.g004

Figure 4. Immunohistochemical detection of DEFA5 protein in intestinal mucosa. No immunostaining can be seen in normal colon (A), while Paneth cells and follicle centers in Peyer’s patches are immunoreactive in normal ileum (B). Mucosal defects with inflammatory cells staining for DEFA5 in untreated UC (C) and Paneth cell loss with diminished DEFA5 staining in active CD (D). Rare DEFA5-positive metaplastic Paneth cells in colonic mucosa of UC responders after infliximab (E). No difference in DEFA5 immunoreactivity when comparing CDi responders with untreated CDi (F). (OM [A]: x100; OM [B–F]: x50). doi:10.1371/journal.pone.0007984.g004
Supporting Information

Appendix S1 A glossary of terms used in the methods. Found at: doi:10.1371/journal.pone.0007984.s001 (0.03 MB DOC)

Figure S1 qPCR analysis of DEFB1 (A), LEAP2 (B), PYY (C), DEFA5 (D), DEFA6 (E) and DEFB4 (F) in intestinal mucosa of IBD patients before and after first infliximab treatment. A line between 2 points represents the change in expression before and after treatment for one patient. R: responders.
Found at: doi:10.1371/journal.pone.0007984.s002 (2.18 MB TIF)

Table S1 A list of the 81 AMP proteins that were investigated in the present study.
Found at: doi:10.1371/journal.pone.0007984.s003 (0.03 MB XLS)

Table S2 The microarray analysis results (FC, p-value and FDR) for all the probe sets representing AMP genes of the performed comparative analyses by LIMMA in and between UC, CD, IBDc and CDi. R: responders, NR: non-responders.
Found at: doi:10.1371/journal.pone.0007984.s004 (0.23 MB XLS)

Table S3 The results (p-value) from the comparative analyses of the qPCR data of DEFB1, LEAP2, PYY, DEFA5, DEFA6 and DEFB4 in intestinal mucosa of IBD patients before and after first infliximab treatment. R: responders, NR: non-responders.
Found at: doi:10.1371/journal.pone.0007984.s005 (0.02 MB XLS)

Author Contributions
Conceived and designed the experiments: IA GDH GVA SV KG FCS PR. Performed the experiments: IA KL RQ LV PL PR. Analyzed the data: IA GDH KL RQ KVS IC GVA SV KG FCS PR. Contributed reagents/materials/analysis tools: IA GDH GVA SV KG FCS PR. Wrote the paper: IA GDH PR.

References
1. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 627–634
2. Kuhn R, Lokhel J, Renneck K, Rayecky K, Muller W (1995) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 73: 263–274
3. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344–1367
4. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, et al. (1993) Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 73: 274–282
5. Sadlack B, Merz H, Schole H, Schimpl A, Feller AC, et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253–261
6. Dianza L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, et al. (1997) T cell receptor-alpha-beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 150: 91–97
7. Rutgeerts P, Geboes K, Peeters M, Penninckx F, et al. (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neutropenic ileum. Lancet 338: 771–774
8. Stappenbeck TS, Stutzin JF, Gearhart JD, et al. (2000) Vascular endothelial growth factor supports growth of colorectal adenomas in vivo. Gastroenterology 119: 1405–1413
9. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel disease. Curr Opin Gastroenterol 20: 473–482
10. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, et al. (2000) Heterogeneous expression of human cathelicidin in inflammatory bowel disease. Proc Natl Acad Sci U S A 102: 18129–18134
11. Rutgeerts P, Geboes K, Peeters M, Penninckx F, et al. (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neutropenic ileum. Lancet 338: 771–774
12. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, et al. (2005) Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 74: 448–453
13. Krause A, Sillard R, Kleemeier B, Kluver E, Maronde E, et al. (2003) Isolation of beta-defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. J Leukoc Biol 74: 448–453
14. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45
15. Sartor RB (2004) Therapeutic modulation of the enteric microflora in inflammatory bowel disease. Curr Opin Gastroenterol 20: 473–482
16. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253–261
17. Sadlack B, Merz H, Schole H, Schimpl A, Feller AC, et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253–261
18. Rutgeerts P, Geboes K, Peeters M, Penninckx F, et al. (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neutropenic ileum. Lancet 338: 771–774
19. Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, et al. (2006) Heterogeneous expression of human cathelicidin in inflammatory bowel disease. Eur J Gastroenterol Hepatol 18: 615–621
20. Schmidt M, Fellermann K, Fritz P, Wiedow O, Stange EF, et al. (2007) Attenuated induction of epithelial and leukocyte serine proteases elafin and secretory leukocyte protease inhibitor in Crohn’s disease. J Leukoc Biol 81: 907–915
21. Nuding S, Fellermann K, Wehkamp J, Stange EF (2007) Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut 56: 1240–1247
22. Fellermann K, Stange DE, Schaefelee E, Schmalzl H, Wehkamp J, et al. (2006) A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79: 439–448
23. Aldous MC, Noble CL, Satsangi J (2009) Downregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS ONE 4: e6285
24. Schauber J, Gallo RL (2008) Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 122: 261–266
25. Yang D, Chen Q, Hooser DM, Staley P, Tucker KD, et al. (2003) Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 74: 448–453
26. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, et al. (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47: 404–409
27. Rutgeerts P, Sandborn WJ, Reagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476
28. Antii I, LK, Toeder G, Quinto R, Van Lommel L, et al. (2009) Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut.
29. Gentleman RC, Carey VJ, Bates DM, Bolstad B, DeStoret M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264
31. Smyth G (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
32. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 65: 289–300
33. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45
34. Radek K, Gallo R (2007) Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol 29: 249–264
35. Krause A, Sillard R, Kleinecke B, Kluver E, Maronde E, et al. (2003) Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci 12: 143–152

PLOS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7984

AMP Expression in IBD Mucosa